Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Polymerase Chain Reaction | 48 | 2024 | 6075 | 6.390 |
Why?
|
DNA Mutational Analysis | 23 | 2022 | 4111 | 4.260 |
Why?
|
Nucleic Acid Denaturation | 16 | 2018 | 110 | 3.040 |
Why?
|
DNA | 36 | 2023 | 7213 | 2.610 |
Why?
|
Nucleic Acid Amplification Techniques | 9 | 2019 | 330 | 1.790 |
Why?
|
Gold | 13 | 2020 | 482 | 1.650 |
Why?
|
Metal Nanoparticles | 10 | 2020 | 399 | 1.540 |
Why?
|
Oligonucleotides | 5 | 2022 | 582 | 1.160 |
Why?
|
Mutation | 37 | 2024 | 30053 | 1.160 |
Why?
|
DNA Probes | 4 | 2019 | 541 | 1.150 |
Why?
|
Pathology, Molecular | 3 | 2018 | 328 | 1.100 |
Why?
|
Oligonucleotide Probes | 5 | 2019 | 416 | 1.100 |
Why?
|
Hydroxyl Radical | 10 | 2001 | 82 | 1.060 |
Why?
|
Microsatellite Instability | 2 | 2021 | 716 | 1.040 |
Why?
|
Alleles | 9 | 2024 | 6864 | 1.030 |
Why?
|
DNA, Neoplasm | 10 | 2023 | 1745 | 1.000 |
Why?
|
ras Proteins | 9 | 2014 | 1054 | 0.980 |
Why?
|
High-Throughput Nucleotide Sequencing | 7 | 2024 | 3639 | 0.960 |
Why?
|
Ultraviolet Rays | 4 | 2024 | 1080 | 0.940 |
Why?
|
Neoplasms | 25 | 2023 | 22173 | 0.900 |
Why?
|
Peptide Nucleic Acids | 4 | 2013 | 26 | 0.890 |
Why?
|
Cold Temperature | 4 | 2014 | 785 | 0.890 |
Why?
|
Tumor Suppressor Protein p53 | 11 | 2015 | 2917 | 0.780 |
Why?
|
Temperature | 8 | 2012 | 2226 | 0.780 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 10 | 2017 | 1745 | 0.760 |
Why?
|
Transition Temperature | 2 | 2011 | 33 | 0.720 |
Why?
|
Polymorphism, Restriction Fragment Length | 5 | 2005 | 767 | 0.720 |
Why?
|
Proto-Oncogene Proteins | 10 | 2014 | 4514 | 0.710 |
Why?
|
Sequence Analysis, DNA | 6 | 2023 | 4740 | 0.600 |
Why?
|
Colonic Neoplasms | 4 | 2018 | 2539 | 0.560 |
Why?
|
DNA Methylation | 6 | 2024 | 4399 | 0.550 |
Why?
|
Dimethyl Sulfoxide | 4 | 2015 | 251 | 0.550 |
Why?
|
DNA Damage | 11 | 2016 | 2449 | 0.530 |
Why?
|
Fluorescent Dyes | 8 | 2006 | 1903 | 0.520 |
Why?
|
Deoxyribonucleases | 1 | 2017 | 211 | 0.520 |
Why?
|
Genetic Testing | 4 | 2014 | 3537 | 0.510 |
Why?
|
Cell Line, Tumor | 19 | 2019 | 16990 | 0.510 |
Why?
|
Radiation-Sensitizing Agents | 4 | 2016 | 350 | 0.510 |
Why?
|
DNA Primers | 7 | 2012 | 2820 | 0.500 |
Why?
|
Endonucleases | 2 | 2016 | 371 | 0.500 |
Why?
|
Lipid Peroxidation | 4 | 2002 | 271 | 0.480 |
Why?
|
Sulfites | 5 | 2017 | 83 | 0.480 |
Why?
|
Delivery Rooms | 2 | 2012 | 38 | 0.470 |
Why?
|
Lung Neoplasms | 15 | 2020 | 13381 | 0.450 |
Why?
|
Genes, p53 | 6 | 2012 | 712 | 0.440 |
Why?
|
Brachytherapy | 5 | 2014 | 1223 | 0.440 |
Why?
|
Adenocarcinoma | 8 | 2011 | 6345 | 0.430 |
Why?
|
Sensitivity and Specificity | 16 | 2016 | 14665 | 0.410 |
Why?
|
Microfluidic Analytical Techniques | 1 | 2018 | 803 | 0.400 |
Why?
|
GATA5 Transcription Factor | 2 | 2010 | 18 | 0.390 |
Why?
|
Fluoresceins | 5 | 2010 | 235 | 0.390 |
Why?
|
Photons | 2 | 2012 | 589 | 0.380 |
Why?
|
Aldehydes | 4 | 2000 | 170 | 0.380 |
Why?
|
Epigenesis, Genetic | 1 | 2024 | 3801 | 0.370 |
Why?
|
Iodine Radioisotopes | 9 | 2012 | 1031 | 0.360 |
Why?
|
Base Sequence | 10 | 2014 | 12441 | 0.350 |
Why?
|
Genome, Human | 5 | 2010 | 4425 | 0.350 |
Why?
|
Radiometry | 9 | 2012 | 813 | 0.340 |
Why?
|
Biotin | 1 | 2011 | 253 | 0.340 |
Why?
|
Infant Formula | 1 | 2011 | 194 | 0.330 |
Why?
|
Breast Feeding | 3 | 2015 | 1360 | 0.330 |
Why?
|
Molecular Probes | 1 | 2011 | 309 | 0.330 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2010 | 698 | 0.320 |
Why?
|
Base Pair Mismatch | 4 | 2004 | 92 | 0.320 |
Why?
|
DNA Glycosylases | 2 | 2000 | 125 | 0.310 |
Why?
|
Humans | 98 | 2024 | 761596 | 0.310 |
Why?
|
Exons | 5 | 2015 | 2391 | 0.310 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2015 | 5305 | 0.300 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2023 | 9280 | 0.290 |
Why?
|
DNA Fragmentation | 1 | 2007 | 237 | 0.280 |
Why?
|
DNA Helicases | 2 | 2002 | 851 | 0.280 |
Why?
|
Flow Cytometry | 5 | 2002 | 5870 | 0.270 |
Why?
|
CpG Islands | 2 | 2010 | 1230 | 0.270 |
Why?
|
Biopsy | 1 | 2018 | 6766 | 0.270 |
Why?
|
Gene Dosage | 2 | 2015 | 1218 | 0.260 |
Why?
|
Limit of Detection | 2 | 2021 | 273 | 0.260 |
Why?
|
Biotinylation | 3 | 2019 | 184 | 0.250 |
Why?
|
Endothelium, Vascular | 3 | 2015 | 4431 | 0.250 |
Why?
|
Coumarins | 6 | 1998 | 118 | 0.250 |
Why?
|
Oligonucleotide Array Sequence Analysis | 7 | 2015 | 3779 | 0.250 |
Why?
|
Antigens, Nuclear | 2 | 2002 | 184 | 0.240 |
Why?
|
Fluorescence | 7 | 2007 | 756 | 0.240 |
Why?
|
DNA, Circular | 1 | 2004 | 97 | 0.240 |
Why?
|
Genetic Techniques | 1 | 2007 | 428 | 0.230 |
Why?
|
Gene Amplification | 1 | 2008 | 1089 | 0.220 |
Why?
|
Radiation Dosage | 8 | 2010 | 1958 | 0.220 |
Why?
|
Fluorescein | 2 | 2002 | 175 | 0.220 |
Why?
|
Neutrons | 5 | 1990 | 77 | 0.220 |
Why?
|
Prostheses and Implants | 2 | 2009 | 1271 | 0.220 |
Why?
|
Monte Carlo Method | 4 | 2015 | 1258 | 0.220 |
Why?
|
Radiotherapy Dosage | 11 | 2014 | 2898 | 0.210 |
Why?
|
Copper | 2 | 1996 | 369 | 0.210 |
Why?
|
Genomic Instability | 2 | 2005 | 709 | 0.210 |
Why?
|
Nucleic Acid Hybridization | 4 | 2010 | 1302 | 0.210 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2024 | 2057 | 0.210 |
Why?
|
Tumor Suppressor Proteins | 4 | 2007 | 2805 | 0.210 |
Why?
|
Workflow | 2 | 2018 | 851 | 0.200 |
Why?
|
Tenascin | 1 | 2002 | 62 | 0.200 |
Why?
|
N-Glycosyl Hydrolases | 2 | 2000 | 68 | 0.200 |
Why?
|
Idoxuridine | 6 | 2002 | 111 | 0.200 |
Why?
|
Neoplasm, Residual | 3 | 2024 | 1008 | 0.200 |
Why?
|
DNA, Complementary | 2 | 2002 | 1991 | 0.200 |
Why?
|
Pyrimidines | 2 | 2024 | 3028 | 0.190 |
Why?
|
Electrons | 4 | 2010 | 265 | 0.190 |
Why?
|
Fluorometry | 4 | 2010 | 99 | 0.190 |
Why?
|
Neovascularization, Pathologic | 5 | 2015 | 2645 | 0.190 |
Why?
|
Histones | 4 | 1996 | 2580 | 0.190 |
Why?
|
Ethanolamines | 1 | 2002 | 153 | 0.190 |
Why?
|
Indicators and Reagents | 2 | 2014 | 462 | 0.190 |
Why?
|
Endothelial Cells | 2 | 2012 | 3549 | 0.190 |
Why?
|
Cell Line | 8 | 2021 | 15601 | 0.190 |
Why?
|
Ligases | 1 | 2002 | 333 | 0.180 |
Why?
|
Artifacts | 4 | 2018 | 1911 | 0.180 |
Why?
|
Bleomycin | 2 | 1999 | 494 | 0.180 |
Why?
|
Technetium Tc 99m Aggregated Albumin | 2 | 1990 | 66 | 0.180 |
Why?
|
Alu Elements | 1 | 2021 | 115 | 0.180 |
Why?
|
Semen | 1 | 2023 | 347 | 0.180 |
Why?
|
Formaldehyde | 3 | 2007 | 358 | 0.170 |
Why?
|
Metals | 2 | 2008 | 719 | 0.170 |
Why?
|
Transistors, Electronic | 2 | 2011 | 22 | 0.170 |
Why?
|
Nucleic Acid Conformation | 1 | 2003 | 902 | 0.160 |
Why?
|
Particle Accelerators | 2 | 2010 | 174 | 0.160 |
Why?
|
Polylysine | 6 | 1997 | 131 | 0.160 |
Why?
|
Gamma Rays | 8 | 2012 | 318 | 0.160 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2019 | 610 | 0.160 |
Why?
|
2,2'-Dipyridyl | 1 | 1998 | 10 | 0.160 |
Why?
|
Molecular Sequence Data | 5 | 2014 | 17635 | 0.160 |
Why?
|
Internet | 1 | 2011 | 3093 | 0.160 |
Why?
|
4-Nitroquinoline-1-oxide | 1 | 1998 | 17 | 0.160 |
Why?
|
Polymorphism, Single Nucleotide | 5 | 2016 | 15936 | 0.160 |
Why?
|
Genotype | 7 | 2009 | 12990 | 0.160 |
Why?
|
Electrophoresis, Capillary | 1 | 2018 | 63 | 0.150 |
Why?
|
Cyclic N-Oxides | 1 | 1998 | 72 | 0.150 |
Why?
|
Phosphatidylethanolamines | 1 | 1998 | 129 | 0.150 |
Why?
|
Radiation Monitoring | 2 | 1990 | 103 | 0.150 |
Why?
|
Microsatellite Repeats | 3 | 2005 | 784 | 0.150 |
Why?
|
Patient Discharge | 1 | 2011 | 3443 | 0.150 |
Why?
|
Radioisotopes | 2 | 2010 | 499 | 0.150 |
Why?
|
Antibiotics, Antineoplastic | 2 | 1999 | 678 | 0.150 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2005 | 1085 | 0.140 |
Why?
|
Thyroid Neoplasms | 2 | 2024 | 2332 | 0.140 |
Why?
|
INDEL Mutation | 1 | 2018 | 266 | 0.140 |
Why?
|
Plasmids | 4 | 2010 | 2269 | 0.140 |
Why?
|
Breast Neoplasms | 6 | 2023 | 21019 | 0.140 |
Why?
|
Nanoparticles | 3 | 2016 | 1958 | 0.140 |
Why?
|
Peroxides | 1 | 1997 | 74 | 0.140 |
Why?
|
Macular Degeneration | 2 | 2015 | 1007 | 0.140 |
Why?
|
Genome | 1 | 2004 | 1740 | 0.130 |
Why?
|
Chromatin | 2 | 1999 | 2961 | 0.130 |
Why?
|
Energy Transfer | 4 | 1989 | 108 | 0.130 |
Why?
|
Spectrometry, Fluorescence | 6 | 1999 | 685 | 0.130 |
Why?
|
Boron Compounds | 1 | 1997 | 182 | 0.130 |
Why?
|
Estrogen Receptor alpha | 1 | 2020 | 583 | 0.130 |
Why?
|
Genes, p16 | 1 | 2015 | 160 | 0.120 |
Why?
|
Erythrocyte Membrane | 1 | 1997 | 439 | 0.120 |
Why?
|
Information Management | 1 | 2015 | 100 | 0.120 |
Why?
|
Silicon Dioxide | 1 | 2016 | 216 | 0.120 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 899 | 0.120 |
Why?
|
Molecular Structure | 4 | 2022 | 1880 | 0.120 |
Why?
|
Erythrocytes | 3 | 2002 | 2413 | 0.120 |
Why?
|
Tissue Fixation | 2 | 2007 | 241 | 0.120 |
Why?
|
Cattle | 5 | 1999 | 3849 | 0.120 |
Why?
|
DNA-Binding Proteins | 5 | 2006 | 9610 | 0.120 |
Why?
|
Radiosurgery | 2 | 2015 | 1342 | 0.120 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2003 | 2425 | 0.120 |
Why?
|
Drug Implants | 1 | 2014 | 230 | 0.120 |
Why?
|
Nucleosomes | 1 | 1998 | 488 | 0.110 |
Why?
|
Paraffin Embedding | 2 | 2006 | 302 | 0.110 |
Why?
|
Reactive Oxygen Species | 1 | 2002 | 2139 | 0.110 |
Why?
|
Apoptosis | 2 | 2015 | 9490 | 0.110 |
Why?
|
DNA Repair | 2 | 2018 | 2046 | 0.110 |
Why?
|
Hydroxides | 1 | 1993 | 46 | 0.110 |
Why?
|
Radiotherapy, High-Energy | 3 | 1994 | 228 | 0.110 |
Why?
|
Male | 21 | 2023 | 360846 | 0.110 |
Why?
|
Biocompatible Materials | 1 | 2021 | 1685 | 0.110 |
Why?
|
Nucleic Acid Heteroduplexes | 2 | 2003 | 46 | 0.110 |
Why?
|
Reproducibility of Results | 7 | 2016 | 20100 | 0.110 |
Why?
|
Piperazines | 1 | 2003 | 2523 | 0.110 |
Why?
|
DNA Ligases | 2 | 2002 | 82 | 0.100 |
Why?
|
Dose-Response Relationship, Radiation | 6 | 2012 | 882 | 0.100 |
Why?
|
Chitosan | 2 | 2010 | 131 | 0.100 |
Why?
|
Light | 1 | 1998 | 1353 | 0.100 |
Why?
|
Time Factors | 9 | 2014 | 39969 | 0.100 |
Why?
|
DNA, Viral | 1 | 1999 | 2202 | 0.100 |
Why?
|
Models, Biological | 5 | 2014 | 9469 | 0.100 |
Why?
|
Doxorubicin | 2 | 2010 | 2224 | 0.100 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2020 | 5314 | 0.100 |
Why?
|
Phantoms, Imaging | 2 | 2012 | 2526 | 0.100 |
Why?
|
Nanomedicine | 1 | 2014 | 289 | 0.090 |
Why?
|
Gadolinium | 1 | 2016 | 960 | 0.090 |
Why?
|
HeLa Cells | 3 | 2012 | 3094 | 0.090 |
Why?
|
Genes, erbB-1 | 1 | 2011 | 162 | 0.090 |
Why?
|
Cone-Beam Computed Tomography | 2 | 2012 | 474 | 0.090 |
Why?
|
Infant Care | 1 | 2012 | 180 | 0.090 |
Why?
|
Solutions | 3 | 1997 | 412 | 0.090 |
Why?
|
Rats, Inbred F344 | 3 | 2002 | 826 | 0.090 |
Why?
|
Free Radicals | 3 | 1997 | 238 | 0.090 |
Why?
|
Benzene Derivatives | 2 | 2002 | 53 | 0.090 |
Why?
|
Nephelometry and Turbidimetry | 1 | 2010 | 91 | 0.090 |
Why?
|
Cell Survival | 6 | 2015 | 5791 | 0.090 |
Why?
|
Coffee | 1 | 2015 | 593 | 0.090 |
Why?
|
Radiation Effects | 1 | 1990 | 69 | 0.090 |
Why?
|
Hydroxylamine | 2 | 2000 | 16 | 0.090 |
Why?
|
Chromatography, High Pressure Liquid | 2 | 2005 | 1541 | 0.090 |
Why?
|
beta-Globins | 1 | 2010 | 111 | 0.090 |
Why?
|
Freezing | 1 | 2011 | 311 | 0.090 |
Why?
|
Personnel, Hospital | 1 | 2012 | 285 | 0.090 |
Why?
|
Oxides | 1 | 2011 | 401 | 0.080 |
Why?
|
Organizational Policy | 1 | 2012 | 432 | 0.080 |
Why?
|
Photochemistry | 2 | 2001 | 239 | 0.080 |
Why?
|
Single-Strand Specific DNA and RNA Endonucleases | 2 | 1999 | 31 | 0.080 |
Why?
|
Radiation Tolerance | 2 | 2015 | 478 | 0.080 |
Why?
|
Radiation Oncology | 1 | 2015 | 563 | 0.080 |
Why?
|
Fiducial Markers | 1 | 2010 | 132 | 0.080 |
Why?
|
Promoter Regions, Genetic | 3 | 2010 | 5790 | 0.080 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2010 | 489 | 0.080 |
Why?
|
Polyglycolic Acid | 1 | 2010 | 406 | 0.080 |
Why?
|
Equipment Design | 2 | 2015 | 3511 | 0.080 |
Why?
|
Postnatal Care | 1 | 2011 | 262 | 0.080 |
Why?
|
Nanotechnology | 1 | 2014 | 714 | 0.080 |
Why?
|
Dental Restoration, Permanent | 1 | 2009 | 130 | 0.080 |
Why?
|
Terminology as Topic | 1 | 2015 | 1530 | 0.080 |
Why?
|
Ascorbic Acid | 3 | 2001 | 655 | 0.080 |
Why?
|
Genomics | 1 | 2004 | 5821 | 0.080 |
Why?
|
beta-Thalassemia | 1 | 2010 | 236 | 0.080 |
Why?
|
Codon | 2 | 2007 | 601 | 0.070 |
Why?
|
Iron | 1 | 1996 | 1793 | 0.070 |
Why?
|
Plastics | 1 | 2008 | 117 | 0.070 |
Why?
|
Antineoplastic Agents | 3 | 2015 | 13642 | 0.070 |
Why?
|
Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2007 | 78 | 0.070 |
Why?
|
Animals | 23 | 2021 | 168475 | 0.070 |
Why?
|
Indoles | 1 | 2015 | 1833 | 0.070 |
Why?
|
Guidelines as Topic | 1 | 2014 | 1386 | 0.070 |
Why?
|
Hydrogen Peroxide | 3 | 2001 | 730 | 0.070 |
Why?
|
Reference Standards | 1 | 2010 | 1003 | 0.070 |
Why?
|
Radiotherapy | 2 | 2010 | 1498 | 0.070 |
Why?
|
Equipment Contamination | 1 | 2008 | 182 | 0.070 |
Why?
|
Quinazolines | 1 | 2013 | 1371 | 0.070 |
Why?
|
Skin Physiological Phenomena | 1 | 2007 | 188 | 0.070 |
Why?
|
Fixatives | 1 | 2006 | 90 | 0.070 |
Why?
|
Activation Analysis | 1 | 1985 | 3 | 0.070 |
Why?
|
Gene Expression Profiling | 5 | 2009 | 9420 | 0.070 |
Why?
|
Genetic Heterogeneity | 1 | 2009 | 732 | 0.070 |
Why?
|
Neutron Activation Analysis | 1 | 1985 | 35 | 0.060 |
Why?
|
Drug Carriers | 1 | 2010 | 706 | 0.060 |
Why?
|
Tumor Cells, Cultured | 3 | 2002 | 6131 | 0.060 |
Why?
|
Sulfonamides | 1 | 2015 | 1979 | 0.060 |
Why?
|
Delayed-Action Preparations | 1 | 2009 | 962 | 0.060 |
Why?
|
Microcirculation | 1 | 2010 | 1272 | 0.060 |
Why?
|
Melanoma | 1 | 2024 | 5709 | 0.060 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2011 | 938 | 0.060 |
Why?
|
Quality Control | 2 | 2012 | 832 | 0.060 |
Why?
|
Pregnancy | 4 | 2022 | 29890 | 0.060 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2010 | 1136 | 0.060 |
Why?
|
Lactic Acid | 1 | 2010 | 1139 | 0.060 |
Why?
|
Genes, ras | 1 | 2007 | 654 | 0.060 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 4576 | 0.060 |
Why?
|
Substrate Specificity | 1 | 2009 | 1791 | 0.060 |
Why?
|
Cell Cycle Proteins | 3 | 2006 | 3449 | 0.060 |
Why?
|
Hypoxanthine Phosphoribosyltransferase | 1 | 2004 | 69 | 0.060 |
Why?
|
Apolipoproteins B | 1 | 2006 | 386 | 0.060 |
Why?
|
Carcinoma | 1 | 2015 | 2330 | 0.060 |
Why?
|
Molecular Probe Techniques | 1 | 2004 | 111 | 0.060 |
Why?
|
Oligonucleotides, Antisense | 1 | 2007 | 461 | 0.060 |
Why?
|
Ferrous Compounds | 2 | 2001 | 41 | 0.060 |
Why?
|
Microspheres | 2 | 2001 | 784 | 0.060 |
Why?
|
Radiotherapy, Conformal | 1 | 2007 | 548 | 0.060 |
Why?
|
Prenatal Diagnosis | 1 | 2010 | 1265 | 0.050 |
Why?
|
HCT116 Cells | 1 | 2004 | 404 | 0.050 |
Why?
|
Developing Countries | 1 | 2015 | 2885 | 0.050 |
Why?
|
Mass Spectrometry | 1 | 2010 | 2192 | 0.050 |
Why?
|
RNA Ligase (ATP) | 1 | 2002 | 9 | 0.050 |
Why?
|
Cell Nucleus | 1 | 2012 | 2910 | 0.050 |
Why?
|
Health Physics | 1 | 2022 | 32 | 0.050 |
Why?
|
Indium Radioisotopes | 2 | 1995 | 113 | 0.050 |
Why?
|
MutS Homolog 2 Protein | 1 | 2003 | 197 | 0.050 |
Why?
|
Bacteriophage T4 | 1 | 2002 | 33 | 0.050 |
Why?
|
Feeding Behavior | 1 | 2015 | 3188 | 0.050 |
Why?
|
Internship and Residency | 1 | 2022 | 5882 | 0.050 |
Why?
|
Vitamin E Deficiency | 1 | 2002 | 30 | 0.050 |
Why?
|
Expressed Sequence Tags | 1 | 2002 | 250 | 0.050 |
Why?
|
Ficusin | 1 | 2001 | 15 | 0.050 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2010 | 1660 | 0.050 |
Why?
|
Female | 14 | 2023 | 392705 | 0.050 |
Why?
|
Radioimmunotherapy | 1 | 2021 | 91 | 0.050 |
Why?
|
Guanine | 1 | 2002 | 279 | 0.050 |
Why?
|
Cesium Radioisotopes | 2 | 1993 | 38 | 0.050 |
Why?
|
Heteroduplex Analysis | 1 | 2000 | 9 | 0.050 |
Why?
|
Edetic Acid | 1 | 2001 | 276 | 0.050 |
Why?
|
Tissue Distribution | 3 | 2014 | 2264 | 0.040 |
Why?
|
Cobalt Radioisotopes | 2 | 1992 | 75 | 0.040 |
Why?
|
Umbelliferones | 1 | 1999 | 11 | 0.040 |
Why?
|
Healthcare Disparities | 1 | 2015 | 3358 | 0.040 |
Why?
|
Specimen Handling | 1 | 2004 | 702 | 0.040 |
Why?
|
Deoxyribonucleotides | 1 | 1999 | 43 | 0.040 |
Why?
|
Succinimides | 2 | 1996 | 81 | 0.040 |
Why?
|
Algorithms | 2 | 2010 | 14033 | 0.040 |
Why?
|
DNA, Superhelical | 1 | 1999 | 51 | 0.040 |
Why?
|
Chromosome Deletion | 1 | 2004 | 1386 | 0.040 |
Why?
|
RNA | 1 | 2009 | 2725 | 0.040 |
Why?
|
Accreditation | 1 | 2022 | 473 | 0.040 |
Why?
|
Mice | 10 | 2021 | 81539 | 0.040 |
Why?
|
Bacteriophage M13 | 1 | 1999 | 39 | 0.040 |
Why?
|
Clinical Laboratory Techniques | 1 | 2004 | 746 | 0.040 |
Why?
|
Health Promotion | 1 | 2011 | 2214 | 0.040 |
Why?
|
Ethidium | 1 | 1998 | 27 | 0.040 |
Why?
|
Drug Delivery Systems | 1 | 2010 | 2226 | 0.040 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2003 | 686 | 0.040 |
Why?
|
Free Radical Scavengers | 2 | 1996 | 211 | 0.040 |
Why?
|
Benzoyl Peroxide | 1 | 1998 | 22 | 0.040 |
Why?
|
Hydroxylamines | 1 | 1998 | 40 | 0.040 |
Why?
|
Endodeoxyribonucleases | 1 | 2019 | 165 | 0.040 |
Why?
|
Nucleic Acid Synthesis Inhibitors | 1 | 1998 | 110 | 0.040 |
Why?
|
Lung | 2 | 2002 | 10002 | 0.040 |
Why?
|
Gliosarcoma | 1 | 1998 | 114 | 0.040 |
Why?
|
Oximes | 1 | 1999 | 303 | 0.040 |
Why?
|
Benzamides | 1 | 2003 | 1371 | 0.040 |
Why?
|
Hydrazines | 1 | 1999 | 224 | 0.040 |
Why?
|
Computer Simulation | 4 | 2014 | 6241 | 0.040 |
Why?
|
Models, Theoretical | 1 | 1989 | 3575 | 0.040 |
Why?
|
Mice, Nude | 2 | 2020 | 3614 | 0.040 |
Why?
|
Infant, Newborn | 3 | 2015 | 26202 | 0.040 |
Why?
|
Health Facilities | 1 | 2022 | 580 | 0.040 |
Why?
|
Phycoerythrin | 1 | 1997 | 9 | 0.040 |
Why?
|
DNA, Single-Stranded | 1 | 1999 | 355 | 0.040 |
Why?
|
Luminescent Measurements | 1 | 1999 | 342 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2012 | 4016 | 0.040 |
Why?
|
Neoplasms, Experimental | 1 | 2002 | 1229 | 0.040 |
Why?
|
Amidines | 1 | 1997 | 29 | 0.040 |
Why?
|
Recurrence | 1 | 2009 | 8466 | 0.040 |
Why?
|
Point Mutation | 1 | 2002 | 1595 | 0.030 |
Why?
|
Glioblastoma | 1 | 2012 | 3483 | 0.030 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2000 | 1693 | 0.030 |
Why?
|
Cricetinae | 2 | 1992 | 2423 | 0.030 |
Why?
|
Chemistry, Physical | 1 | 1996 | 154 | 0.030 |
Why?
|
Adenine | 1 | 2002 | 987 | 0.030 |
Why?
|
Molecular Weight | 1 | 1999 | 2186 | 0.030 |
Why?
|
Osteosarcoma | 1 | 2002 | 897 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2002 | 10766 | 0.030 |
Why?
|
Colorectal Neoplasms | 3 | 2012 | 6938 | 0.030 |
Why?
|
Singlet Oxygen | 1 | 1996 | 58 | 0.030 |
Why?
|
Chemical Phenomena | 1 | 1996 | 507 | 0.030 |
Why?
|
Radionuclide Imaging | 2 | 1990 | 1972 | 0.030 |
Why?
|
Carbon Radioisotopes | 1 | 1997 | 561 | 0.030 |
Why?
|
Cost Savings | 1 | 2001 | 913 | 0.030 |
Why?
|
Tumor Burden | 1 | 2021 | 1892 | 0.030 |
Why?
|
Rats | 3 | 2002 | 23741 | 0.030 |
Why?
|
Homozygote | 1 | 2000 | 1776 | 0.030 |
Why?
|
Brain Neoplasms | 2 | 2012 | 9032 | 0.030 |
Why?
|
Solvents | 1 | 1996 | 295 | 0.030 |
Why?
|
Receptor, erbB-2 | 1 | 2006 | 2557 | 0.030 |
Why?
|
Organizations, Nonprofit | 1 | 2015 | 105 | 0.030 |
Why?
|
Viral Proteins | 1 | 2002 | 1804 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2004 | 3430 | 0.030 |
Why?
|
Purines | 1 | 1998 | 607 | 0.030 |
Why?
|
X-Rays | 1 | 2015 | 307 | 0.030 |
Why?
|
In Situ Nick-End Labeling | 1 | 2015 | 613 | 0.030 |
Why?
|
Liver | 1 | 1990 | 7528 | 0.030 |
Why?
|
Microscopy, Fluorescence | 1 | 2002 | 2645 | 0.030 |
Why?
|
DNA, Recombinant | 1 | 1995 | 455 | 0.030 |
Why?
|
Head and Neck Neoplasms | 1 | 2009 | 2894 | 0.030 |
Why?
|
Radiation, Ionizing | 2 | 2006 | 251 | 0.030 |
Why?
|
Fluorescence Polarization | 1 | 1994 | 140 | 0.030 |
Why?
|
Macaca fascicularis | 1 | 2016 | 903 | 0.030 |
Why?
|
Prostate | 1 | 2002 | 1773 | 0.030 |
Why?
|
Macromolecular Substances | 1 | 1996 | 1434 | 0.030 |
Why?
|
Gene Deletion | 1 | 2001 | 2665 | 0.030 |
Why?
|
Heterozygote | 1 | 2000 | 2787 | 0.030 |
Why?
|
Ovarian Neoplasms | 2 | 2006 | 4878 | 0.030 |
Why?
|
Avidin | 1 | 1993 | 43 | 0.030 |
Why?
|
Africa | 1 | 2015 | 709 | 0.030 |
Why?
|
Molecular Conformation | 1 | 1994 | 544 | 0.030 |
Why?
|
Transfection | 2 | 2015 | 5774 | 0.030 |
Why?
|
Capacity Building | 1 | 2015 | 258 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 2003 | 3713 | 0.030 |
Why?
|
Endothelium | 1 | 2015 | 765 | 0.030 |
Why?
|
Methods | 1 | 1993 | 1067 | 0.030 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2019 | 946 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2014 | 5247 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2015 | 422 | 0.030 |
Why?
|
Polymorphism, Genetic | 1 | 2003 | 4243 | 0.030 |
Why?
|
Neoadjuvant Therapy | 1 | 2023 | 2828 | 0.020 |
Why?
|
Lasers | 1 | 2016 | 952 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2020 | 3605 | 0.020 |
Why?
|
Nuclear Proteins | 2 | 2006 | 5799 | 0.020 |
Why?
|
United States | 3 | 2022 | 72340 | 0.020 |
Why?
|
Eye | 1 | 2015 | 712 | 0.020 |
Why?
|
United Nations | 1 | 2012 | 150 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2015 | 1827 | 0.020 |
Why?
|
Prospective Studies | 3 | 2023 | 54423 | 0.020 |
Why?
|
Glioma | 1 | 2006 | 3455 | 0.020 |
Why?
|
Radiation | 1 | 1990 | 49 | 0.020 |
Why?
|
Radiopharmaceuticals | 3 | 2010 | 2650 | 0.020 |
Why?
|
Mice, SCID | 1 | 2015 | 2626 | 0.020 |
Why?
|
Carcinoma, Papillary | 1 | 2015 | 785 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 2022 | 2373 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 1996 | 2231 | 0.020 |
Why?
|
Water | 2 | 1994 | 1411 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 2002 | 2529 | 0.020 |
Why?
|
Drug Stability | 1 | 2010 | 291 | 0.020 |
Why?
|
Serum Albumin | 1 | 1993 | 672 | 0.020 |
Why?
|
Thallium Radioisotopes | 1 | 1989 | 138 | 0.020 |
Why?
|
Polymethyl Methacrylate | 1 | 2010 | 131 | 0.020 |
Why?
|
Ascites | 1 | 1991 | 338 | 0.020 |
Why?
|
Fast Neutrons | 1 | 1989 | 18 | 0.020 |
Why?
|
Autoradiography | 1 | 1990 | 728 | 0.020 |
Why?
|
Technetium | 1 | 1989 | 317 | 0.020 |
Why?
|
Technology, Radiologic | 1 | 1990 | 160 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2006 | 8554 | 0.020 |
Why?
|
Weights and Measures | 1 | 1989 | 41 | 0.020 |
Why?
|
Half-Life | 1 | 1990 | 651 | 0.020 |
Why?
|
Drug Compounding | 1 | 2010 | 246 | 0.020 |
Why?
|
Dental Amalgam | 1 | 2009 | 66 | 0.020 |
Why?
|
Radioactivity | 1 | 1989 | 59 | 0.020 |
Why?
|
Hydrophobic and Hydrophilic Interactions | 1 | 2010 | 398 | 0.020 |
Why?
|
Certification | 1 | 2012 | 418 | 0.020 |
Why?
|
Contrast Media | 1 | 2002 | 5307 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 3810 | 0.020 |
Why?
|
Dental Materials | 1 | 2009 | 113 | 0.020 |
Why?
|
Radioactive Fallout | 1 | 1988 | 7 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2021 | 3878 | 0.020 |
Why?
|
Nuclear Reactors | 1 | 1988 | 8 | 0.020 |
Why?
|
Ethylenes | 1 | 1988 | 43 | 0.020 |
Why?
|
Blotting, Western | 1 | 2015 | 5035 | 0.020 |
Why?
|
Risk Assessment | 1 | 2009 | 23996 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 1990 | 1379 | 0.020 |
Why?
|
Escherichia coli | 1 | 2000 | 4217 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2020 | 8527 | 0.020 |
Why?
|
Adsorption | 1 | 2008 | 197 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2009 | 17904 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 4580 | 0.020 |
Why?
|
Relative Biological Effectiveness | 1 | 1989 | 312 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2002 | 12794 | 0.020 |
Why?
|
Surface Properties | 1 | 2010 | 1161 | 0.020 |
Why?
|
Information Dissemination | 1 | 2015 | 1126 | 0.020 |
Why?
|
Cohort Studies | 2 | 2024 | 41495 | 0.020 |
Why?
|
Accidents | 1 | 1988 | 165 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2009 | 11122 | 0.020 |
Why?
|
Urban Population | 1 | 2015 | 2036 | 0.020 |
Why?
|
Neoplasm Transplantation | 2 | 2002 | 2016 | 0.020 |
Why?
|
Radiation Protection | 1 | 1990 | 424 | 0.020 |
Why?
|
World Health Organization | 1 | 2012 | 1322 | 0.020 |
Why?
|
Survival Rate | 1 | 2020 | 12723 | 0.020 |
Why?
|
Collagen Type II | 1 | 2006 | 148 | 0.020 |
Why?
|
Polyethylenes | 1 | 1988 | 290 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2015 | 4915 | 0.020 |
Why?
|
Oxygen | 1 | 1996 | 4227 | 0.010 |
Why?
|
Equipment Failure Analysis | 1 | 2007 | 847 | 0.010 |
Why?
|
Methylation | 1 | 2006 | 1084 | 0.010 |
Why?
|
Muscles | 1 | 1988 | 1576 | 0.010 |
Why?
|
Kinetics | 1 | 2010 | 6374 | 0.010 |
Why?
|
Paclitaxel | 1 | 2010 | 1732 | 0.010 |
Why?
|
Radiobiology | 1 | 2002 | 90 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2015 | 11076 | 0.010 |
Why?
|
Boston | 1 | 2015 | 9327 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2015 | 7828 | 0.010 |
Why?
|
Adult | 3 | 2023 | 221210 | 0.010 |
Why?
|
Models, Immunological | 1 | 2002 | 513 | 0.010 |
Why?
|
Biomedical Research | 1 | 2015 | 3429 | 0.010 |
Why?
|
Prognosis | 1 | 2020 | 29629 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39106 | 0.010 |
Why?
|
Gene Silencing | 1 | 2004 | 1509 | 0.010 |
Why?
|
Injections, Intralesional | 1 | 1998 | 280 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2015 | 18255 | 0.010 |
Why?
|
Software | 1 | 1990 | 4434 | 0.010 |
Why?
|
Stereotaxic Techniques | 1 | 1998 | 555 | 0.010 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2006 | 2898 | 0.010 |
Why?
|
Cell Division | 1 | 2002 | 4465 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2012 | 7391 | 0.010 |
Why?
|
Spectrophotometry | 1 | 1994 | 309 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2002 | 2386 | 0.010 |
Why?
|
Biophysical Phenomena | 1 | 1994 | 320 | 0.010 |
Why?
|
Biophysics | 1 | 1994 | 380 | 0.010 |
Why?
|
Gene Expression | 1 | 2006 | 7581 | 0.010 |
Why?
|
Chelating Agents | 1 | 1995 | 387 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2006 | 4937 | 0.010 |
Why?
|
Infant | 1 | 2015 | 36193 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2016 | 36426 | 0.010 |
Why?
|
Models, Statistical | 1 | 2007 | 5079 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2020 | 80647 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2004 | 7593 | 0.010 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1995 | 2496 | 0.010 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 1991 | 718 | 0.010 |
Why?
|
Ukraine | 1 | 1988 | 149 | 0.000 |
Why?
|
Greece | 1 | 1988 | 340 | 0.000 |
Why?
|
Gene Expression Regulation | 1 | 2004 | 11904 | 0.000 |
Why?
|
Binding Sites | 1 | 1995 | 6056 | 0.000 |
Why?
|
Cell Cycle | 1 | 1991 | 2932 | 0.000 |
Why?
|
Risk Factors | 1 | 1990 | 74213 | 0.000 |
Why?
|
Survival Analysis | 1 | 1991 | 10090 | 0.000 |
Why?
|
Brain | 1 | 1998 | 27121 | 0.000 |
Why?
|